Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.

Boni E ElewskiLluis PuigMargaret MordinIsabelle GilloteauBintu SherifTodd FoxAri GnanasakthyCharis PapavassilisBruce E Strober

Published in: The Journal of dermatological treatment (2017)

These results show that PASI 90-100 is a relevant therapeutic goal in moderate to severe psoriasis compared to PASI 75-89 when considering patients' QOL.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
early onset
ankylosing spondylitis
high intensity
systemic lupus erythematosus
disease activity